Drug Patents Expiring in 2025

1. Abilify patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(3 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Aug 27, 2011
New Indication(I-616) Nov 19, 2012
New Indication(I-633) Feb 16, 2014
M(M-137) Jun 09, 2017
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE) Dec 12, 2021
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 20 September, 2006

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Asimtufii patent expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA Methods for administering aripiprazole
Mar, 2025

(5 months from now)




Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Use of aripiprazole in extended release injectable suspension

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Abilify Maintena Kit patent expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

4. Abraxane patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820788

(Pediatric)

BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Apr, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-658) Oct 11, 2015
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
M(M-14) Dec 06, 2022
Pediatric Exclusivity(PED) Jun 06, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

5. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(10 months from now)

US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(10 months from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

6. Admelog Solostar patent expiration

ADMELOG SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 11, 2020

Drugs and Companies using INSULIN LISPRO ingredient

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ADMELOG SOLOSTAR family patents

Family Patents

7. Adrenaclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166334 IMPAX Medicine injection apparatuses
Jan, 2025

(3 months from now)

US10166344 IMPAX Injection needle assembly
Jan, 2025

(3 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

ADRENACLICK family patents

Family Patents

8. Advair Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Jan, 2025

(2 months from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(8 months from now)




Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

ADVAIR HFA family patents

Family Patents

9. Aemcolo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(6 months from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(6 months from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(6 months from now)

US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2023
Generating Antibiotic Incentives Now(GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE

More Information on Dosage

AEMCOLO family patents

Family Patents

10. Afinitor patent expiration

AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment
Nov, 2025

(1 year, 19 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-638) May 05, 2014
New Indication(I-650) Apr 26, 2015
New Indication(I-655) Jul 20, 2015
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Orphan Drug Exclusivity(ODE-11) May 05, 2018
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

Dosage: TABLET

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

11. Airduo Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

12. Airduo Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

13. Aklief patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 2 months from now)

US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor

Dosage: CREAM

More Information on Dosage

AKLIEF family patents

Family Patents

14. Amitiza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-670) Apr 19, 2016
M(M-225) Apr 26, 2021

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome

Dosage: CAPSULE

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

15. Amondys 45 patent expiration

AMONDYS 45's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48960 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)

US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2026
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping

Dosage: SOLUTION

More Information on Dosage

AMONDYS 45 family patents

Family Patents

16. Ampyra patent expiration

AMPYRA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8663685 MERZ PHARMS GMBH Sustained release aminopyridine composition
Jan, 2025

(3 months from now)

US8440703 MERZ PHARMS GMBH Methods of using sustained release aminopyridine compositions
Apr, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2015
Orphan Drug Exclusivity(ODE) Jan 22, 2017

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage

AMPYRA family patents

Family Patents

17. Amrix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Feb, 2025

(4 months from now)




Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 February, 2007

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of AMRIX before it's drug patent expiration?
More Information on Dosage

AMRIX family patents

Family Patents

18. Anoro Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(6 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(6 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(9 months from now)

US7439393

(Pediatric)

GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

19. Antara (micronized) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(6 months from now)




Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

20. Apidra Solostar patent expiration

APIDRA SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

21. Aptiom patent expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702536 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(6 months from now)

US10695354 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(6 months from now)

US10675287 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(6 months from now)

US11364247 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures

Dosage: TABLET

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

22. Arcapta Neohaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

23. Arikayce Kit patent expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

24. Armonair Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

25. Armonair Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(4 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(7 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

26. Astepro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(1 year, 1 month from now)

US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2012
M(M-129) Aug 30, 2016
New Patient Population(NPP) Feb 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

27. Astepro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MEDA PHARMS Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2012
M(M-129) Aug 30, 2016
New Patient Population(NPP) Feb 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 August, 2009

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

28. Astepro Allergy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 1 month from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 1 month from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

29. Auvi-q patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(3 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(5 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(6 months from now)

US9149579 KALEO INC Devices, systems and methods for medicament delivery
Jul, 2025

(9 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method of treating allergic reaction via injection

Dosage: SOLUTION

More Information on Dosage

AUVI-Q family patents

Family Patents

30. Baxdela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(11 months from now)

US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
New Indication(I-815) Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET; POWDER

More Information on Dosage

BAXDELA family patents

Family Patents

31. Belviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8697686 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980881 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Method for chronic weight management by controlling weight gain

Dosage: TABLET

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

32. Belviq Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8697686 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980881 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management by controlling weight gain

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

33. Bepreve patent expiration

BEPREVE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784789 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Jan, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 08, 2014

Drugs and Companies using BEPOTASTINE BESILATE ingredient

NCE-1 date: 08 September, 2013

Market Authorisation Date: 08 September, 2009

Treatment: NA

Dosage: SOLUTION/DROPS

How can I launch a generic of BEPREVE before it's drug patent expiration?
More Information on Dosage

BEPREVE family patents

Family Patents

34. Biktarvy patent expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 4 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

35. Bosulif patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 1 month from now)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2017
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
New Indication(I-923) Sep 26, 2026
New Product(NP) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 26 September, 2023

Treatment: A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy

Dosage: TABLET; CAPSULE

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

36. Breo Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 30, 2018
New Indication(I-708) Apr 30, 2018
New Chemical Entity Exclusivity(NCE) May 10, 2018
M(M-202) May 15, 2020
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema

Dosage: POWDER

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

37. Brilinta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2016
New Indication(I-714) Sep 03, 2018
New Strength(NS) Sep 03, 2018
New Indication(I-851) May 28, 2023
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

38. Brisdelle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 28, 2016

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

39. Brixadi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545832 BRAEBURN Lipid depot formulations
Jun, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

BRIXADI family patents

Family Patents

40. Bydureon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(8 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

41. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(8 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve gl...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

42. Bydureon Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(8 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

43. Cabenuva Kit patent expiration

CABENUVA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

44. Children's Astepro Allergy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 1 month from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 1 month from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ASTEPRO ALLERGY family patents

Family Patents

45. Chlorhexidine Gluconate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7717889 SAGE PRODS Disinfectant delivery system and method of providing alcohol free disinfection
Feb, 2025

(4 months from now)




Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

Family Patents

46. Ciprodex patent expiration

CIPRODEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650 SANDOZ Method of treating middle ear infections
Jun, 2025

(7 months from now)




Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS

How can I launch a generic of CIPRODEX before it's drug patent expiration?
More Information on Dosage

CIPRODEX family patents

Family Patents

47. Combivent Respimat patent expiration

COMBIVENT RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

48. Combogesic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532036 AFT PHARMS LTD Combination composition
Sep, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 01, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET

More Information on Dosage

COMBOGESIC family patents

Family Patents

49. Complera patent expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Dec 13, 2016

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

50. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

51. Coreg Cr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209 WAYLIS THERAP Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(10 months from now)




Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents

52. Cresemba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(1 year, 18 days from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(1 year, 18 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE) Mar 06, 2022
ODE*(ODE*) Mar 06, 2022
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Patient Population(NPP) Dec 08, 2026
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE-453) Dec 08, 2030
Orphan Drug Exclusivity(ODE-454) Dec 08, 2030
Orphan Drug Exclusivity(ODE-458) Dec 08, 2030
Orphan Drug Exclusivity(ODE-459) Dec 08, 2030
Pediatric Exclusivity(PED) Jun 08, 2031

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 22 November, 2022

Treatment: NA

Dosage: CAPSULE; POWDER

More Information on Dosage

CRESEMBA family patents

Family Patents

53. Daytrana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(11 months from now)

US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(11 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 29, 2013

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE

How can I launch a generic of DAYTRANA before it's drug patent expiration?
More Information on Dosage

DAYTRANA family patents

Family Patents

54. Defencath patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696182 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
May, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
Generating Antibiotic Incentives Now(GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 15 November, 2032

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION

More Information on Dosage

DEFENCATH family patents

Family Patents

55. Descovy patent expiration

DESCOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 4 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 28, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Indication(I-812) Oct 03, 2022
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: NA

Dosage: TABLET

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

56. Differin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Feb, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Mar 17, 2013
RTO(RTO) Jul 08, 2019

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: Topical treatment of acne vulgaris

Dosage: GEL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

57. Diprivan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(7 months from now)




Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

58. Dojolvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 30, 2025
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID

More Information on Dosage

DOJOLVI family patents

Family Patents

59. Duaklir Pressair patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46417 COVIS Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

60. Durysta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673341 ABBVIE Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT

More Information on Dosage

DURYSTA family patents

Family Patents

61. Duvyzat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7329689 ITALFARMACO SPA Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
Jan, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2029
Orphan Drug Exclusivity(ODE-473) Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: NA

Dosage: SUSPENSION

More Information on Dosage

DUVYZAT family patents

Family Patents

62. Duzallo patent expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(10 months from now)




Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

DUZALLO family patents

Family Patents

63. Edarbi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents

64. Edarbyclor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

65. Edurant patent expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125879

(Pediatric)

JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Oct, 2025

(1 year, 8 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Aug 26, 2018
M(M-223) Feb 01, 2021

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy

Dosage: TABLET

More Information on Dosage

EDURANT family patents

Family Patents

66. Edurant Ped patent expiration

EDURANT PED's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(6 months from now)




Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 March, 2024

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...

Dosage: TABLET, FOR SUSPENSION

More Information on Dosage

EDURANT PED family patents

Family Patents

67. Elelyso patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8790641 PFIZER Production of high mannose proteins in plant culture and therapeutic uses thereof
Oct, 2025

(1 year, 5 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 01, 2017
New Patient Population(NPP) Aug 27, 2017

Drugs and Companies using TALIGLUCERASE ALFA ingredient

NCE-1 date: 01 May, 2016

Market Authorisation Date: 01 May, 2012

Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.

Dosage: POWDER

More Information on Dosage

ELELYSO family patents

Family Patents

68. Embeda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(8 months from now)

US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

69. Entresto patent expiration

ENTRESTO's oppositions filed in EPO
ENTRESTO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(3 months from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

70. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE's oppositions filed in EPO
ENTRESTO SPRINKLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS Methods of treatment and pharmaceutical composition
Jan, 2025

(3 months from now)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: NA

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

71. Epanova patent expiration

EPANOVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(3 months from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(3 months from now)

US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2019

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

NCE-1 date: 05 May, 2018

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia

Dosage: CAPSULE

More Information on Dosage

EPANOVA family patents

Family Patents

72. Epiduo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Nov, 2025

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 08, 2011
New Patient Population(NPP) Feb 01, 2016

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: NA

Dosage: GEL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

73. Epipen patent expiration

EPIPEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(10 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(10 months from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(10 months from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(10 months from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(10 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of EPIPEN before it's drug patent expiration?
More Information on Dosage

EPIPEN family patents

Family Patents

74. Epipen Jr. patent expiration

EPIPEN JR.'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(10 months from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(10 months from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(10 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(10 months from now)

US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(10 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of EPIPEN JR. before it's drug patent expiration?
More Information on Dosage

EPIPEN JR. family patents

Family Patents

75. Erivedge patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2017

Drugs and Companies using VISMODEGIB ingredient

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma

Dosage: CAPSULE

More Information on Dosage

ERIVEDGE family patents

Family Patents

76. Evzio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(3 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(5 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(6 months from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO family patents

Family Patents

77. Evzio (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(3 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(5 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(6 months from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

78. Exondys 51 patent expiration

EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)

US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)

US8486907 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE) Sep 19, 2023
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by restoring or increasing functional dystrophin protein production; (...

Dosage: SOLUTION

More Information on Dosage

EXONDYS 51 family patents

Family Patents

79. Exxua patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7538116 FABRE KRAMER Treatment of sexual disorders
Sep, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2028

Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient

NCE-1 date: 23 September, 2027

Market Authorisation Date: 22 September, 2023

Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

EXXUA family patents

Family Patents

80. Fanapt patent expiration

FANAPT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone
Sep, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2014
M(M-180) May 26, 2019
New Indication(I-939) Apr 02, 2027

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine

Dosage: TABLET

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

81. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(5 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(8 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(a year from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

82. Femtrace patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Oct, 2025

(11 months from now)




Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET

More Information on Dosage

FEMTRACE family patents

Family Patents

83. Fiasp Flextouch patent expiration

FIASP FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 7 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 29, 2020
New Patient Population(NPP) Dec 19, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

84. Filsuvez patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828444 CHIESI Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
Jun, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2028
Orphan Drug Exclusivity(ODE-460) Dec 18, 2030